The CEO of Germany's Merck KGaA said a recovery in sales growth at its existing business means it can take a cautious approach when it comes to buying other companies, which are expensively priced.

DARMSTADT, Germany, January 22, 2025--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the introduction of a Caregiver Leave Benefit as an ...

DARMSTADT, Germany — Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the introduction of a Caregiver Leave Benefit as an additional family-friendly offering ...

In a report released on January 13, David Evans from Kepler Capital maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target of €182.00. The company’s shares ...

In an interview on CNBC’s Mad Money, Robert Davis said Merck’s (MRK) current pipeline is the most diversified it has been in recent history.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Merck KGaA and Pfizer have got the fourth checkpoint inhibitor to market after the US regulator approved their avelumab for a rare form of skin cancer. The FDA’s approval of avelumab ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Jan 18 (Reuters) - Robert F. Kennedy Jr. played an instrumental role in organizing mass litigation against drugmaker Merck over its Gardasil vaccine, a strategy that faces its first test in a Los ...

1 This initiative builds on the recent rollout of the global Fertility Benefit at Merck KGaA, Darmstadt, Germany and its affiliates, and advances the company’s journey to provide an inclusive suite of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) therapies after its drug candidate pimicotinib cleared a phase 3 trial.